id: NEW:substance_use_treatment_guideline_gaps_to_NEW:naltrexone_treatment_availability_pregnant
name: Substance Use Treatment Guideline Gaps for Pregnant Populations â†’ Naltrexone Treatment Availability
  for Pregnant Individuals
from_node:
  node_id: NEW:substance_use_treatment_guideline_gaps
  node_name: Substance Use Treatment Guideline Gaps for Pregnant Populations
to_node:
  node_id: NEW:naltrexone_treatment_availability_pregnant
  node_name: Naltrexone Treatment Availability for Pregnant Individuals
direction: negative
category: political
mechanism_pathway:
- 'Step 1: Absence of national guidelines for naltrexone use in pregnancy creates policy vacuum'
- 'Step 2: Providers lack institutional support and evidence-based protocols for treating pregnant patients'
- 'Step 3: Provider uncertainty and liability concerns reduce willingness to prescribe'
- 'Step 4: Fewer sites offer naltrexone to pregnant individuals'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: 'Chloe Deflorimonte et al. 2023. "National Provider Survey: Use of Naltrexone for
    Pregnant Individuals with Substance Use Disorders." https://doi.org/10.1097/ADM.0000000000001225'
  supporting_citations:
  - Additional citations require full-text access - abstract mentions lack of national guidelines as identified
    barrier
  - Additional citations require full-text access
  - Additional citations require full-text access
  doi: 10.1097/ADM.0000000000001225
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: The lack of national guidelines for using naltrexone in pregnant patients was identified
  as a barrier by 14.1% of responding providers, contributing to limited availability of this treatment
  option.
quantitative_effects:
  effect_size:
    value: 14.1
    type: percentage_change
  sample_size: 78
structural_competency:
  equity_implications: This mechanism identifies a policy-level structural determinant. The absence of
    national guidelines represents a failure of medical institutions and regulatory bodies to provide
    adequate guidance for treating pregnant individuals with SUD. This policy gap places the burden on
    individual providers to navigate complex clinical decisions without institutional support, ultimately
    limiting patient access to potentially beneficial treatments. The structural solution requires investment
    in research and guideline development at the national level.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.211135'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
